- Amplia Therapeutics (ATX) receives the final ethics clearance to conduct a phase two clinical trial
- The company gained approval from a second Human Research Ethics Committee (HREC) for the clinical trial of its Focal Adhesion Kinase (FAK) inhibitor, AMP945
- Amplia says this second HREC approval will allow it to recruit patients more rapidly and generate early efficacy results in people with pancreatic cancer
- With all HREC approvals complete, Amplia says it will now switch its focus to the trial’s execution phase
- Amplia Therapeutics last traded at 12 cents on May 12
Amplia Therapeutics (ATX) has received the final ethics clearance to conduct its phase two clinical trial.
The company gained approval from a second Human Research Ethics Committee (HREC) to conduct the clinical trial of its Focal Adhesion Kinase (FAK) inhibitor, AMP945.
The drug is used for first-line patients with advanced pancreatic cancer. Amplia said FAK is an increasingly important target in the field of cancer immunology.
“This second HREC approval will allow us to recruit patients more rapidly and begin to generate early efficacy and safety results in people with pancreatic cancer,” Amplia’s CEO and Managing Director John Lambert said.
“Our focus is now on timely recruitment and execution of a high-quality trial that will support our future development plans for AMP945 in this very dangerous disease.”
The approval covers sites in Victoria, and follows HREC approval to initiate the trial at sites in New South Wales.
With all HREC approvals complete, Amplia said it will now switch its focus to the trial’s execution phase.
Amplia Therapeutics last traded at 12 cents on May 12.